Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison
Despite the limitations due to the use of ITC and the comparison between clinical trials and real-world cohorts, the present analysis suggests potential benefits in terms of vision gain and CST reduction in naïve nAMD patients treated with faricimab compared with SoC in a real-world setting.
Authors
- Laura Bianchino
- Mariacristina Parravano (ORCID: https://orcid.org/0000-0002-2223-7311)
- Carlotta Galeone (ORCID: https://orcid.org/0000-0003-1934-5167)
- Massimo Nicolò (ORCID: https://orcid.org/0000-0002-7824-3091)
- Paolo Lanzetta (ORCID: https://orcid.org/0000-0003-3746-141X)
- Federica Turati (ORCID: https://orcid.org/0000-0002-5841-5773)
- Stela Vujosevic (ORCID: https://orcid.org/0000-0001-6773-9967)
- Emilia Sicari
Institutions
- University of Udine (IT)
- University of Milan (IT)
- MultiMedica (IT)
- Fondazione G.B. Bietti (IT)
- Cancer Research And Biostatistics (US)
- Roche (Italy) (IT)
- Istituto Europeo di Microchirurgia Oculare (IT)
- Ospedale Policlinico San Martino (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Drug Target Insights
- Published
- 2024-12-12
- DOI
- https://doi.org/10.33393/dti.2024.3213
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.08